Scans

Tools

Home

Charts

Watchlist

Products

Apollo Hospitals Enterprise Ltd

APOLLOHOSP

NSE

₹7,600.00-1.30%21 Oct 2026 at 3:57 PM

Reports

Hospitals

Apollo Hospitals Enterprise Ltd

APOLLOHOSP

NSE

₹7,600.00

-1.30%

21 Oct 2026 at 3:57 PM

SOICxStockScans Reports

Ask AI

Hospitals

Indices

Business Overview: What the company does, in plain English.Growth Catalysts: The forward growth drivers and triggers.Guidance Report: Management guidance vs outcomes.Forensic Report: Accounting quality and red flags.Deep Dive Report: In-depth business analysis.

Apollo Hospitals is not just a hospital chain - it is India’s largest and most complete private healthcare ecosystem, built over four decades to touch a patient at every point of care, from a neighbourhood pharmacy to a robotic brain surgery. It began in 1983 when Dr. Prathap C Reddy opened India’s first corporate hospital in Chennai, defying the notion that world-class care was only for the wealthy, and that same year it opened its first pharmacy, planting the seeds of a model that would eventually span hospitals, clinics, diagnostics, pharmacies, and a digital health platform. The recurring approach is to build a clinical asset of the highest complexity, earn trust, and then extend that trust into simpler, higher-volume touchpoints - pharmacies, diagnostics, primary clinics, and a digital app - so that the patient stays inside the Apollo system for life.

Business segments

Four engines at different stages - a mature hospital network that anchors the group, a pharmacy-distribution and digital platform being merged into a separate listed entity, a retail-health and diagnostics chain that feeds the hospitals, and a small but growing insurance and consumer-products layer - each built to capture a different part of the patient’s healthcare journey.

1. Healthcare Services: the high-acuity hospital network that earns the group’s reputation

Complex, life-saving procedures - cardiac, cancer, neuro, transplant - generate the clinical brand that makes every other part of the ecosystem credible.

Fee-for-service on high-intensity episodes - the division earns revenue per inpatient stay, with an average of ₹187,208 per case in Q4 FY26, driven more by the complexity of the case mix than by simply filling more beds.
“CONGO-T” specialties concentrate the skill - Cardiac, Oncology, Neurosciences, Gastroenterology, Orthopedics, and Transplant together form the clinical core; in FY26, cardiology alone brought in 19% of in-patient revenue and oncology 16%, meaning nearly two of every five rupees came from heart and cancer care.
Technology as a magnet for patients and surgeons - the network houses South East Asia’s first proton therapy centre in Chennai, South Asia’s first ZAP-X radiosurgery platform for brain tumours, and India’s first AI-Precision Oncology Centre, all of which pull in complex cases that community hospitals cannot handle.
Quality standards benchmarked to the world’s best - the Apollo Standards of Clinical Care (TASCC) scorecard tracks 40 clinical parameters against institutions like the Cleveland Clinic and Mayo Clinic, while JCI accreditation at eight hospitals makes the quality promise externally verifiable.
A physical footprint that is still expanding - 78 hospitals with 10,970 capacity beds as of March 2026, with four new hospitals commissioned in FY26 alone and 3,415 more beds under development across 11 projects, including a greenfield hospital in Varanasi, a Build, Operate and Manage agreement in Mumbai, and a mix of greenfield, lease facility, and brownfield expansion in Bengaluru.

2. Apollo HealthCo: the pharmacy backbone and digital front door, soon to be a standalone listed company

A wholesale distribution engine that supplies 7,289 pharmacies and a digital platform with 47 million registered users - together forming an omni-channel health platform that is being merged with India’s largest pharma wholesaler and listed separately.

Exclusive supplier to a nationwide pharmacy chain - the distribution business procures pharmaceuticals, FMCG, and private-label products and is the sole supplier to Apollo Pharmacies Limited under a long-term contract, giving it a procurement-cost advantage over local chemists and regional chains.
Private label lifts margins - roughly 15.3% of omni-channel pharmacy sales in Q4 FY26 came from Apollo’s own private-label and generic products, which carry better economics than selling third-party brands.
The digital platform turns trust into daily transactions - Apollo 24/7 handles approximately 15,000 doctor consultations and 51,600 medicine orders every day, with a customer-acquisition cost brought down to ₹250-400 per user by leaning on the Apollo brand and its 6,000-plus physical outlets rather than pure digital marketing spend.
A Clinical Intelligence Engine that only Apollo could build - the platform’s AI-powered decision-support tool understands over 1,200 diseases and 800 symptoms prevalent in South Asia, trained on Apollo’s own clinical knowledge base and peer-reviewed by more than 500 of its specialists, a data moat no pure-tech competitor can replicate.
The Keimed merger creates a distribution giant - a composite scheme of arrangement will demerge Apollo HealthCo, merge it with Keimed (which serves 70,000-plus pharmacies across 18 states with 96 distribution centres), and list the combined entity as Apollo Healthtech Limited, with AHEL shareholders owning 42.1% of the new company.

3. Apollo Health & Lifestyle: the out-of-hospital network that catches patients early and feeds the hospitals

A multi-brand chain of clinics, diagnostics labs, dialysis units, dental centres, and day-surgery facilities that operates on a hub-and-spoke model - treating everyday needs while identifying patients who need escalated hospital care.

Diagnostics as the high-volume entry point - 2,501 centres including 114 labs and over 2,350 collection centres processed more than 8.6 million tests, with a central reference lab using AI to auto-validate 77% of results across 164 tests, speeding up turnaround in a business where speed wins customers.
Each sub-brand targets a specific recurring need - Apollo Sugar manages diabetes with connected glucometers and long-term care packages, Apollo Dialysis runs units often under public-private partnership models with state governments, and Apollo Spectra performs short-stay surgeries in orthopedics, urology, and bariatrics, all on a fee-for-service basis.
A feeder system for the tertiary hospitals - the hub-and-spoke design means a patient diagnosed at an Apollo Clinic or diagnostic centre can be referred directly into the main hospital network for complex treatment, keeping the patient within the Apollo ecosystem.
The maternity and fertility business is being reshaped - in May 2026, AHLL agreed to sell its Apollo Cradle and Apollo Fertility centres to Cloudnine for cash of ₹7,650 million plus a roughly 9.9% equity stake in the combined entity, creating one of India’s largest maternity and fertility platforms while AHLL retains a stake in the upside.

4. Insurance and consumer products: early-stage bets on the edges of the ecosystem

A corporate insurance agency and a newly acquired FMCG distribution arm extend the Apollo brand into health coverage and everyday wellness products, both still nascent.

Insurance sold without a field force - Apollo 24|7 Insurance Services Limited, incorporated in September 2024, acts as a corporate agent for life, general, and health insurance, distributing policies through digital channels and a 300-seat call centre rather than an agent network, keeping distribution costs low.
Consumer products ride the pharmacy shelf space - Apollo Consumer Products Ltd, acquired in March 2026, will trade and distribute FMCG goods including food, personal care, and wellness products through the same physical retail and digital networks that already move pharmaceuticals, turning existing shelf space into a new revenue line.

Group structure and partners

A listed parent company with a web of subsidiaries that hold individual hospital assets, a soon-to-be-separated pharmacy and digital entity backed by Advent International, and a retail-health subsidiary that just became wholly owned - all governed by non-compete boundaries that keep each engine in its lane.

Hospitals are held in asset-specific subsidiaries - individual hospitals in Kolkata, Lucknow, Bangalore, Ahmedabad, Guwahati, Indore, and other cities sit inside separate subsidiary companies, many with local minority partners, which isolates project-level risk and makes future stake sales or acquisitions cleaner.
Advent International owns a slice of the pharmacy-digital business - the private-equity firm invested ₹2,475 crore in Apollo HealthCo in September 2024 for approximately 16.9%, and will hold 12.1% of the post-merger Apollo Healthtech entity, aligning external capital with the listing catalyst.
A non-compete framework keeps the engines from colliding - under a Business Framework Agreement, AHEL cannot run an e-commerce or retail pharmacy business outside its hospital pharmacies, while Apollo HealthCo cannot deliver physical healthcare services; the Apollo 24/7 platform remains the exclusive digital front-end for the entire group.

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹1,09,276Cr

Close Price

₹7,600.00

Industry

Hospitals

Price To Earnings

52.29

Price To Sales

4.13

Revenue

₹26,430Cr

Rev Gr TTM

Revenue Growth TTM

17.20%

PAT Gr TTM

PAT Growth TTM

33.20%

Upcoming Results on

4 Nov 2026

Consolidated

Standalone

Numbers

Percentage

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	4,847	4,851	4,944	5,086	5,589	5,527	5,592	5,842	6,304	6,477	6,606	7,044
Growth YoY Revenue Growth YoY%	14.0	13.8	14.9	15.1	15.3	13.9	13.1	14.9	12.8	17.2	18.1	20.6
Expenses ExpensesCr	4,219	4,237	4,303	4,411	4,774	4,765	4,823	4,990	5,362	5,512	5,595	5,951
Operating Profit Operating ProfitCr	628	614	641	675	816	762	770	852	941	965	1,011	1,092
OPM OPM%	12.9	12.7	13.0	13.3	14.6	13.8	13.8	14.6	14.9	14.9	15.3	15.5
Other Income Other IncomeCr	26	29	37	49	44	69	72	54	61	49	54	62
Interest Expense Interest ExpenseCr	111	113	119	116	118	110	115	108	110	113	119	120
Depreciation DepreciationCr	163	167	190	177	185	185	211	215	218	219	224	235
PBT PBTCr	379	363	368	430	557	536	516	583	675	682	722	799
Tax TaxCr	130	109	110	115	162	157	101	142	181	166	170	188
PAT PATCr	249	254	258	316	396	379	415	441	494	516	551	610
Growth YoY PAT Growth YoY%	16.9	56.6	77.5	82.0	59.0	49.1	60.4	39.8	24.8	36.1	33.0	38.4
NPM NPM%	5.1	5.2	5.2	6.2	7.1	6.9	7.4	7.5	7.8	8.0	8.3	8.7
EPS EPS₹	16.2	17.1	17.6	21.2	26.3	25.9	27.1	30.1	33.2	34.9	36.8	40.4

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	4,847	4,851	4,944	5,086	5,589	5,527	5,592	5,842	6,304	6,477	6,606	7,044
Growth YoY Revenue Growth YoY%	14.0	13.8	14.9	15.1	15.3	13.9	13.1	14.9	12.8	17.2	18.1	20.6
Expenses ExpensesCr	4,219	4,237	4,303	4,411	4,774	4,765	4,823	4,990	5,362	5,512	5,595	5,951
Operating Profit Operating ProfitCr	628	614	641	675	816	762	770	852	941	965	1,011	1,092
OPM OPM%	12.9	12.7	13.0	13.3	14.6	13.8	13.8	14.6	14.9	14.9	15.3	15.5
Other Income Other IncomeCr	26	29	37	49	44	69	72	54	61	49	54	62
Interest Expense Interest ExpenseCr	111	113	119	116	118	110	115	108	110	113	119	120
Depreciation DepreciationCr	163	167	190	177	185	185	211	215	218	219	224	235
PBT PBTCr	379	363	368	430	557	536	516	583	675	682	722	799
Tax TaxCr	130	109	110	115	162	157	101	142	181	166	170	188
PAT PATCr	249	254	258	316	396	379	415	441	494	516	551	610
Growth YoY PAT Growth YoY%	16.9	56.6	77.5	82.0	59.0	49.1	60.4	39.8	24.8	36.1	33.0	38.4
NPM NPM%	5.1	5.2	5.2	6.2	7.1	6.9	7.4	7.5	7.8	8.0	8.3	8.7
EPS EPS₹	16.2	17.1	17.6	21.2	26.3	25.9	27.1	30.1	33.2	34.9	36.8	40.4

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	6,215	7,256	8,243	9,617	11,247	10,560	14,663	16,613	19,059	21,794	25,229	26,430
Growth Revenue Growth%	20.0	16.8	13.6	16.7	16.9	-6.1	38.9	13.3	14.7	14.3	15.8	17.2
Expenses ExpensesCr	5,527	6,527	7,450	8,554	9,660	9,423	12,478	14,563	16,669	18,772	21,459	22,420
Operating Profit Operating ProfitCr	688	729	793	1,064	1,587	1,137	2,185	2,050	2,391	3,022	3,769	4,010
OPM OPM%	11.1	10.0	9.6	11.1	14.1	10.8	14.9	12.3	12.5	13.9	14.9	15.2
Other Income Other IncomeCr	88	65	32	32	225	106	372	90	126	233	217	226
Interest Expense Interest ExpenseCr	180	257	295	327	533	449	379	381	449	459	450	462
Depreciation DepreciationCr	264	314	359	396	620	573	601	615	687	758	876	897
PBT PBTCr	332	222	171	373	660	221	1,578	1,144	1,381	2,039	2,661	2,877
Tax TaxCr	97	91	112	173	225	85	477	256	446	534	658	705
PAT PATCr	235	131	60	199	435	136	1,101	888	935	1,505	2,003	2,172
Growth PAT Growth%	-27.7	-44.3	-54.6	234.5	118.3	-68.7	709.6	-19.4	5.3	61.0	33.1	33.2
NPM NPM%	3.8	1.8	0.7	2.1	3.9	1.3	7.5	5.3	4.9	6.9	7.9	8.2
EPS EPS₹	17.0	15.9	8.4	17.0	32.7	10.7	73.4	57.0	62.5	100.6	135.0	145.3

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	6,215	7,256	8,243	9,617	11,247	10,560	14,663	16,613	19,059	21,794	25,229	26,430
Growth Revenue Growth%	20.0	16.8	13.6	16.7	16.9	-6.1	38.9	13.3	14.7	14.3	15.8	17.2
Expenses ExpensesCr	5,527	6,527	7,450	8,554	9,660	9,423	12,478	14,563	16,669	18,772	21,459	22,420
Operating Profit Operating ProfitCr	688	729	793	1,064	1,587	1,137	2,185	2,050	2,391	3,022	3,769	4,010
OPM OPM%	11.1	10.0	9.6	11.1	14.1	10.8	14.9	12.3	12.5	13.9	14.9	15.2
Other Income Other IncomeCr	88	65	32	32	225	106	372	90	126	233	217	226
Interest Expense Interest ExpenseCr	180	257	295	327	533	449	379	381	449	459	450	462
Depreciation DepreciationCr	264	314	359	396	620	573	601	615	687	758	876	897
PBT PBTCr	332	222	171	373	660	221	1,578	1,144	1,381	2,039	2,661	2,877
Tax TaxCr	97	91	112	173	225	85	477	256	446	534	658	705
PAT PATCr	235	131	60	199	435	136	1,101	888	935	1,505	2,003	2,172
Growth PAT Growth%	-27.7	-44.3	-54.6	234.5	118.3	-68.7	709.6	-19.4	5.3	61.0	33.1	33.2
NPM NPM%	3.8	1.8	0.7	2.1	3.9	1.3	7.5	5.3	4.9	6.9	7.9	8.2
EPS EPS₹	17.0	15.9	8.4	17.0	32.7	10.7	73.4	57.0	62.5	100.6	135.0	145.3

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	70	70	70	70	70	72	72	72	72	72	72
Reserves ReservesCr	3,261	3,240	3,182	3,264	3,270	4,531	5,551	6,126	6,864	8,140	9,408
Current Liabilities Current LiabilitiesCr	1,250	963	1,567	1,956	2,337	2,038	2,434	3,325	4,665	4,579	6,481
Non Current Liabilities Non Current LiabilitiesCr	2,701	3,718	3,662	3,759	5,531	4,577	4,932	4,572	4,768	7,426	5,741
Total Liabilities Total LiabilitiesCr	7,360	8,119	8,613	9,183	11,338	11,417	13,269	14,428	16,753	20,657	22,197
Current Assets Current AssetsCr	1,975	2,129	2,220	2,282	2,647	3,641	4,061	4,337	5,280	7,029	6,900
Non Current Assets Non Current AssetsCr	5,385	5,990	6,393	6,901	8,692	7,775	9,209	10,091	11,473	13,629	15,297
Total Assets Total AssetsCr	7,360	8,119	8,613	9,183	11,338	11,417	13,269	14,428	16,753	20,657	22,197

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	70	70	70	70	70	72	72	72	72	72	72
Reserves ReservesCr	3,261	3,240	3,182	3,264	3,270	4,531	5,551	6,126	6,864	8,140	9,408
Current Liabilities Current LiabilitiesCr	1,250	963	1,567	1,956	2,337	2,038	2,434	3,325	4,665	4,579	6,481
Non Current Liabilities Non Current LiabilitiesCr	2,701	3,718	3,662	3,759	5,531	4,577	4,932	4,572	4,768	7,426	5,741
Total Liabilities Total LiabilitiesCr	7,360	8,119	8,613	9,183	11,338	11,417	13,269	14,428	16,753	20,657	22,197
Current Assets Current AssetsCr	1,975	2,129	2,220	2,282	2,647	3,641	4,061	4,337	5,280	7,029	6,900
Non Current Assets Non Current AssetsCr	5,385	5,990	6,393	6,901	8,692	7,775	9,209	10,091	11,473	13,629	15,297
Total Assets Total AssetsCr	7,360	8,119	8,613	9,183	11,338	11,417	13,269	14,428	16,753	20,657	22,197

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	597	623	537	905	1,293	1,265	1,696	1,377	1,920	2,136	2,856
Investing Cash Flow Investing Cash FlowCr	-888	-1,152	-405	-711	-289	-863	-847	-871	-1,537	-3,383	-2,148
Financing Cash Flow Financing Cash FlowCr	330	477	-109	-215	-910	-340	-792	-633	-311	1,319	-478
Net Cash Flow Net Cash FlowCr	39	-52	24	-20	95	61	57	-127	72	73	230
Free Cash Flow Free Cash FlowCr	-393	-46	-84	233	782	984	1,044	253	785	439	925
CFO To PAT CFO To PAT%	253.9	474.8	901.6	454.4	297.4	929.9	154.0	155.1	205.4	141.9	142.6
CFO To EBITDA CFO To EBITDA%	86.8	85.5	67.7	85.1	81.5	111.2	77.6	67.2	80.3	70.7	75.8

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	597	623	537	905	1,293	1,265	1,696	1,377	1,920	2,136	2,856
Investing Cash Flow Investing Cash FlowCr	-888	-1,152	-405	-711	-289	-863	-847	-871	-1,537	-3,383	-2,148
Financing Cash Flow Financing Cash FlowCr	330	477	-109	-215	-910	-340	-792	-633	-311	1,319	-478
Net Cash Flow Net Cash FlowCr	39	-52	24	-20	95	61	57	-127	72	73	230
Free Cash Flow Free Cash FlowCr	-393	-46	-84	233	782	984	1,044	253	785	439	925
CFO To PAT CFO To PAT%	253.9	474.8	901.6	454.4	297.4	929.9	154.0	155.1	205.4	141.9	142.6
CFO To EBITDA CFO To EBITDA%	86.8	85.5	67.7	85.1	81.5	111.2	77.6	67.2	80.3	70.7	75.8

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	18,426	16,231	14,784	16,986	15,830	41,739	64,937	61,963	91,331	95,219	1,06,809	1,09,276
Price To Earnings Price To Earnings	78.0	73.5	125.9	72.0	34.8	277.5	61.5	75.7	101.7	65.9	55.0	52.3
Price To Sales Price To Sales	3.0	2.2	1.8	1.8	1.4	4.0	4.4	3.7	4.8	4.4	4.2	4.1
Price To Book Price To Book	5.5	4.9	4.6	5.1	4.8	9.1	11.6	10.0	13.2	11.6	11.3	11.5
EV To EBITDA EV To EBITDA	30.1	25.7	22.3	18.9	11.8	39.7	31.2	32.0	40.0	33.7	30.3	29.4
Profitability Ratios Profitability Ratios
GPM GPM%	44.2	40.3	41.2	41.4	40.9	35.4	36.2	36.3	36.3	35.9	34.7	34.7
OPM OPM%	11.1	10.0	9.6	11.1	14.1	10.8	14.9	12.3	12.5	13.9	14.9	15.2
NPM NPM%	3.8	1.8	0.7	2.1	3.9	1.3	7.5	5.3	4.9	6.9	7.9	8.2
ROCE ROCE%	8.6	7.6	7.1	10.3	17.8	7.7	20.2	14.5	14.9	15.5	17.3	17.3
ROE ROE%	7.1	4.0	1.8	6.0	13.0	3.0	19.6	14.3	13.5	18.3	21.1	21.1
ROA ROA%	3.2	1.6	0.7	2.2	3.8	1.2	8.3	6.2	5.6	7.3	9.0	9.0
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	18,426	16,231	14,784	16,986	15,830	41,739	64,937	61,963	91,331	95,219	1,06,809	1,09,276
Price To Earnings Price To Earnings	78.0	73.5	125.9	72.0	34.8	277.5	61.5	75.7	101.7	65.9	55.0	52.3
Price To Sales Price To Sales	3.0	2.2	1.8	1.8	1.4	4.0	4.4	3.7	4.8	4.4	4.2	4.1
Price To Book Price To Book	5.5	4.9	4.6	5.1	4.8	9.1	11.6	10.0	13.2	11.6	11.3	11.5
EV To EBITDA EV To EBITDA	30.1	25.7	22.3	18.9	11.8	39.7	31.2	32.0	40.0	33.7	30.3	29.4
Profitability Ratios Profitability Ratios
GPM GPM%	44.2	40.3	41.2	41.4	40.9	35.4	36.2	36.3	36.3	35.9	34.7	34.7
OPM OPM%	11.1	10.0	9.6	11.1	14.1	10.8	14.9	12.3	12.5	13.9	14.9	15.2
NPM NPM%	3.8	1.8	0.7	2.1	3.9	1.3	7.5	5.3	4.9	6.9	7.9	8.2
ROCE ROCE%	8.6	7.6	7.1	10.3	17.8	7.7	20.2	14.5	14.9	15.5	17.3	17.3
ROE ROE%	7.1	4.0	1.8	6.0	13.0	3.0	19.6	14.3	13.5	18.3	21.1	21.1
ROA ROA%	3.2	1.6	0.7	2.2	3.8	1.2	8.3	6.2	5.6	7.3	9.0	9.0
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

	APOLLOHOSP	MANIPALHOS	MAXHEALTH	ASTERDM	FORTIS	NH	MEDANTA
Market CapitalizationMkt CapCr	1,09,276	82,547	79,802	56,672	55,036	35,252	33,136
Close PriceClose₹	7,600.00	627.55	819.90	650.15	729.00	1,725.00	1,232.40
IndustryIndustry	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals
Price To EarningsPE	52.29	88.02	54.70	105.20	52.52	42.93	59.54
Price To SalesPS	4.13	7.99	9.16	11.62	5.79	3.89	7.08
RevenueRevenueCr	26,430	10,336	8,712	4,876	9,506	9,072	4,683
Revenue Growth TTMRev Gr TTM%	17.2%		16.0%	15.7%	17.5%	59.6%	21.3%
PAT Growth TTMPAT Gr TTM%	33.2%		27.0%	3.9%	18.6%	3.9%	3.4%

	APOLLOHOSP	MANIPALHOS	MAXHEALTH	ASTERDM	FORTIS	NH	MEDANTA
Market CapitalizationMkt CapCr	1,09,276	82,547	79,802	56,672	55,036	35,252	33,136
Close PriceClose₹	7,600.00	627.55	819.90	650.15	729.00	1,725.00	1,232.40
IndustryIndustry	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals
Price To EarningsPE	52.29	88.02	54.70	105.20	52.52	42.93	59.54
Price To SalesPS	4.13	7.99	9.16	11.62	5.79	3.89	7.08
RevenueRevenueCr	26,430	10,336	8,712	4,876	9,506	9,072	4,683
Revenue Growth TTMRev Gr TTM%	17.2%		16.0%	15.7%	17.5%	59.6%	21.3%
PAT Growth TTMPAT Gr TTM%	33.2%		27.0%	3.9%	18.6%	3.9%	3.4%

FY2026

FY2024

FY2023

FY2022

FY2021

FY2020

FY2026

Jun 26